Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.64 | 5.08 | 9.99 | 8.29 | 5.93 | 4.72 | 5.43 | 6.87 | 16.55 | 16.05 | 7.73 | 8.28 |
| Expenses | 8.91 | 5.65 | 9.66 | 8.11 | 6.72 | 5.51 | 6.04 | 6.78 | 14.94 | 15.21 | 8.39 | 8.23 |
| Operating Profit | -0.27 | -0.57 | 0.33 | 0.18 | -0.79 | -0.79 | -0.61 | 0.09 | 1.61 | 0.84 | -0.66 | 0.05 |
| OPM % | -3.12% | -11.22% | 3.30% | 2.17% | -13.32% | -16.74% | -11.23% | 1.31% | 9.73% | 5.23% | -8.54% | 0.60% |
| Other Income | 0.20 | 0.13 | 0.19 | 0.15 | 0.22 | 0.19 | 0.18 | 0.32 | 0.14 | 19.16 | 0.34 | 0.30 |
| Interest | 0.01 | 0.02 | -0.00 | -0.00 | -0.00 | 0.01 | -0.00 | 0.03 | -0.00 | 0.02 | 0.18 | 0.01 |
| Depreciation | 0.09 | 0.08 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.06 | 0.05 | 0.06 | 0.04 | 0.03 |
| Profit before tax | -0.17 | -0.54 | 0.43 | 0.25 | -0.65 | -0.69 | -0.51 | 0.32 | 1.70 | 19.92 | -0.54 | 0.31 |
| Tax % | -5.88% | 3.70% | -9.30% | -12.00% | -0.00% | 1.45% | 1.96% | 12.50% | -2.35% | 18.27% | 31.48% | -9.68% |
| Net Profit | -0.16 | -0.56 | 0.47 | 0.28 | -0.64 | -0.70 | -0.53 | 0.27 | 1.74 | 16.27 | -0.70 | 0.34 |
| EPS in Rs | -0.23 | -0.82 | 0.69 | 0.41 | -0.94 | -1.03 | -0.78 | 0.40 | 2.55 | 23.83 | -1.03 | 0.50 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 14 | 19 | 24 | 20 | 16 | 17 | 27 | 31 | 24 | 47 | 49 |
| Expenses | 13 | 14 | 18 | 23 | 19 | 16 | 19 | 29 | 31 | 26 | 45 | 47 |
| Operating Profit | 1 | 0 | 1 | 1 | 1 | -0 | -2 | -2 | -1 | -2 | 2 | 2 |
| OPM % | 5% | 1.0% | 3.5% | 3.0% | 4.1% | -0.4% | -10% | -6% | -2.7% | -8% | 4.0% | 3.8% |
| Other Income | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 20 | 20 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 1 | 1 | 1 | 0 | -2 | -1 | -1 | -2 | 21 | 21 |
| Tax % | 83% | 37% | 16% | 6% | 45% | 33% | -1% | -12% | -6% | -1% | 18% | |
| Net Profit | 0 | 0 | 1 | 1 | 1 | 0 | -2 | -1 | -1 | -2 | 18 | 18 |
| EPS in Rs | 0.06 | 0.23 | 0.83 | 1.14 | 0.79 | 0.45 | -2.27 | -1.85 | -0.76 | -2.33 | 25.74 | 25.85 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 13% | 24% | 20% | 112% | ||
| Compounded Profit Growth | % | % | % | 237% | ||
| Stock Price CAGR | 16% | 26% | 49% | 167% | ||
| Return on Equity | -6% | -16% | -19% | -31% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves | 6 | 5 | 5 | 5 | 6 | 7 | 7 | 5 | 4 | 3 | 2 | 15 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Liabilities | 6 | 7 | 8 | 10 | 20 | 20 | 8 | 9 | 17 | 21 | 13 | 7 |
| Total Liabilities | 19 | 19 | 20 | 22 | 33 | 34 | 22 | 21 | 28 | 31 | 22 | 30 |
| Fixed Assets | 16 | 14 | 14 | 14 | 14 | 13 | 13 | 13 | 13 | 12 | 12 | 1 |
| CWIP | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Other Assets | 4 | 5 | 6 | 8 | 19 | 20 | 9 | 8 | 16 | 19 | 9 | 29 |
| Total Assets | 19 | 19 | 20 | 22 | 33 | 34 | 22 | 21 | 28 | 31 | 22 | 30 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 0 | -0 | 1 | 0 | 0 | 0 | -0 | 1 | 0 | -3 | 22 |
| Cash from Investing Activity | -0 | -0 | -0 | -1 | -0 | -0 | -0 | 0 | -0 | -0 | -0 | -12 |
| Cash from Financing Activity | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 1 |
| Net Cash Flow | 0 | 0 | -0 | 0 | -0 | -0 | 0 | -0 | 0 | -0 | -3 | 11 |
| Free Cash Flow | 0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 | 1 | 0 | -3 | 9 |
| CFO/OP | 59% | 68% | 21% | 153% | 32% | 41% | -817% | 1% | -42% | -13% | 127% | 1,153% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 48 | 78 | 91 | 73 | 179 | 226 | 96 | 69 | 100 | 96 | 47 | 40 |
| Inventory Days | 80 | 12 | 56 | 43 | 135 | 125 | 66 | 112 | 103 | 126 | 57 | 48 |
| Days Payable | 185 | 216 | 293 | 249 | 403 | 374 | 166 | 214 | 269 | 298 | 224 | 23 |
| Cash Conversion Cycle | -56 | -127 | -146 | -133 | -89 | -24 | -4 | -33 | -65 | -76 | -120 | 64 |
| Working Capital Days | -79 | -64 | -43 | -34 | -13 | 7 | 8 | -17 | -39 | -43 | -71 | 62 |
| ROCE % | 3% | 2% | 2% | 6% | 7% | 8% | 4% | -12% | -12% | -5% | -16% | 16% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% | 73.51% |
| DIIs | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 26.43% | 26.43% | 26.43% | 26.43% | 26.43% | 26.43% | 26.43% | 26.42% | 26.44% | 26.44% | 26.43% | 26.43% |
| No. of Shareholders | 20,722 | 20,688 | 20,682 | 20,642 | 20,596 | 20,612 | 20,620 | 20,512 | 20,497 | 20,404 | 20,301 | 20,286 |
Fundamentals
Market Cap₹ 60.1 Cr.
Current Price₹ 88.0
Stock P/E27.4
Book Value₹ 32.4
ROCE16.4 %
ROE-31.1 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)112%
Compounded Profit Growth (TTM)237%
Standalone figures.
Valuation
Market capRs 63 Cr
Enterprise valueRs 53 Cr
P/E (TTM)3.57x
Price to book2.85x
Price to sales1.30x
EV / EBITDA2.44x
EV / EBIT2.46x
EV / sales1.09x
Price to cash flow2.93x
Earnings yield27.98%
P/E, 3-year average2.92x
P/B, 3-year average2.18x
P/E, 5-year average2.92x
P/B, 5-year average1.95x
Profitability
Operating margin (excl. other income)3.96%
Operating margin (incl. other income)46.22%
EBITDA margin44.83%
Pre-tax margin44.00%
Net profit margin36.31%
Net margin, latest quarter4.11%
ROE113.94%
ROCE135.19%
ROA68.07%
ROE, 3-year average30.77%
ROCE, 3-year average38.03%
ROA, 3-year average20.11%
ROE, 5-year average13.85%
ROCE, 5-year average18.00%
ROA, 5-year average9.61%
ROIC (approx.)145.22%
Tax rate17.81%
Other income / net worth90.27%
Growth
Sales growth (latest year)93.72%
Sales CAGR, 3 years19.85%
Sales CAGR, 5 years23.85%
Profit CAGR, 5 years124.22%
Sales growth QoQ7.12%
Sales growth YoY (latest quarter)20.52%
Profit growth YoY (latest quarter)25.93%
Per share
EPS (TTM)Rs 25.85
EPS (latest year)Rs 25.74
EPS (latest quarter)Rs 0.50
EPS, 3-year averageRs 7.55
EPS, 5-year averageRs 3.71
Book value per shareRs 32.37
Sales per shareRs 71.20
Cash flow per shareRs 31.58
Free cash flow per shareRs 13.18
Efficiency
Asset turnover1.57x
Fixed asset turnover44.54x
Inventory turnover9.15x
Inventory days40 days
Debtor days40 days
Debtors turnover9.20x
Creditor days23 days
Cash conversion cycle64 days
Working capital days62 days
Leverage
Total debtRs 1 Cr
Cash and bankRs 11 Cr
Net debtRs -10 Cr
Debt to equity0.05x
Net debt / EBITDA-0.45x
Interest coverage98.23x
Owners' fund to total sources73.52%
Debt to assets3.73%
Cash flow
Cash from Operating Activity (latest year)Rs 22 Cr
Cash from Investing Activity (latest year)Rs -12 Cr
Cash from Financing Activity (latest year)Rs 1 Cr
Net Cash Flow (latest year)Rs 11 Cr
Free cash flow (latest year)Rs 9 Cr
FCFE (approx.: FCF + change in debt)Rs 10 Cr
Cash from ops / profit, 5 years1.67x
Sales to cash flow2.19x
Statement figures
Net sales (TTM)Rs 49 Cr
Net sales (latest year)Rs 47 Cr
Sales (latest quarter)Rs 8 Cr
Operating profit excl. other income (latest year)Rs 2 Cr
Operating profit (latest quarter)Rs 0 Cr
Other income (TTM)Rs 20 Cr
EBITDA (TTM)Rs 22 Cr
PBDT (TTM)Rs 22 Cr
Profit before tax (TTM)Rs 21 Cr
Tax (latest year)Rs 4 Cr
Net profit (TTM)Rs 18 Cr
Net profit (latest year)Rs 18 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 0 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 40 Cr
Total expenditure (latest year)Rs 45 Cr
Total income (latest year)Rs 67 Cr
Share capitalRs 7 Cr
ReservesRs 15 Cr
Shareholders' fundsRs 22 Cr
Total assetsRs 30 Cr
Net blockRs 1 Cr
ReceivablesRs 5 Cr
InventoryRs 4 Cr
Other liabilitiesRs 7 Cr
Shares outstanding (crore)0.68
Ownership
Promoter holding73.51% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 3.6 is at the 7th percentile of its own 5.9-year range
(median 33.5, low 2.9, high 190.3).
P/B 2.85 is at the 84th percentile (median 1.59).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 523620 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.8% | -2.8% | +6.6 pts |
| 1 month | +21.6% | -6.8% | +28.4 pts |
| 3 months | -8.0% | -7.6% | -0.4 pts |
| 3 years | +242.3% | +14.2% | +228.2 pts |
| 5 years | +208.5% | +27.9% | +180.6 pts |
Red flags
F-score 7 of 8| look | Profit leans on other income Other income was 93% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹8 Cr +20.5% vs Jun 2025.
Net profit ₹0 Cr +25.9%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Phaarmasia Ltd?
Phaarmasia Ltd (523620) has a market capitalisation of Rs 60.1 Cr. at the 2026-10-01 close.
What is the P/E ratio of Phaarmasia Ltd?
Phaarmasia Ltd trades at a P/E of 27.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Phaarmasia Ltd's latest quarterly results?
In the Jun 2026 quarter, Phaarmasia Ltd sales was Rs 8 Cr (+20.5% vs Jun 2025) and net profit was Rs 0 Cr.